Filing Details
- Accession Number:
- 0001209191-20-009834
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-14 19:40:17
- Reporting Period:
- 2020-02-13
- Accepted Time:
- 2020-02-14 19:40:17
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1080709 | Arena Pharmaceuticals Inc | ARNA | Pharmaceutical Preparations (2834) | 232908305 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1677036 | Robert Kevin Lind | C/O Arena Pharmaceuticals, Inc. 6154 Nancy Ridge Drive San Diego CA 92121 | Executive Vp And Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-02-13 | 2,500 | $19.40 | 5,957 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-02-13 | 2,000 | $35.60 | 7,957 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-13 | 4,500 | $55.00 | 3,457 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2020-02-13 | 2,500 | $0.00 | 2,500 | $19.40 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2020-02-13 | 2,000 | $0.00 | 2,000 | $35.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 77,500 | 2023-06-15 | No | 4 | M | Direct | |
| 128,000 | 2025-01-19 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
- The options vest over four years, with 25% of the shares subject to the option vesting on June 15, 2017, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
- The options vest over four years, with 25% of the shares subject to the option vesting on January 19, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
Billionaire Hedge Funds
